Letrozole as a Treatment of Endometrial Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cervical Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 3/16/2015 |
| Start Date: | October 2009 |
| End Date: | August 2012 |
| Contact: | Lloyd H. Smith, MD, PhD |
| Email: | lhsmith@ucdavis.edu |
| Phone: | 916-734-6945 |
Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole
blocks estrogen production in the body. The purpose of this study is to determine if the
investigators can predict which patients might benefit from Letrozole treatment by studying
the many different forms of the estrogen receptor molecule that exist within the cancer
tissues. To participate in this study, the patients must be 40 years of age or older and
have biopsy-proven endometrial carcinoma, either well differentiated or moderately
differentiated forms. Also, to be eligible to participate in this study, the patients need
to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will
need a blood test (FSH) to confirm that they have gone into menopause.
blocks estrogen production in the body. The purpose of this study is to determine if the
investigators can predict which patients might benefit from Letrozole treatment by studying
the many different forms of the estrogen receptor molecule that exist within the cancer
tissues. To participate in this study, the patients must be 40 years of age or older and
have biopsy-proven endometrial carcinoma, either well differentiated or moderately
differentiated forms. Also, to be eligible to participate in this study, the patients need
to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will
need a blood test (FSH) to confirm that they have gone into menopause.
Inclusion Criteria:
- FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
- Post menopausal status must be demonstrated
- Signed informed consent
Exclusion Criteria:
- FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the
endometrium
- Younger than 40 or postmenopausal status not established
- Pregnant or breastfeeding
We found this trial at
2
sites
University of California-Davis As we begin our second century, UC Davis is poised to become...
Click here to add this to my saved trials
University of California-Davis As we begin our second century, UC Davis is poised to become...
Click here to add this to my saved trials